EXEL vs TNGX
EXEL: Exelixis is a commercial-stage oncology biotechnology company with a strong focus on developing small-molecule treatments for various types of cancer. TNGX: A precision oncology firm using a proprietary functional genomics platform to discover and develop targeted small-molecule therapies for genetically defined cancers.
Side-by-side fundamentals
| Metric | EXEL | TNGX | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $54.08 | $23.88 | |
| Market cap as of 2026-08-24 | $13.4B | $4.0B | |
| P/E as of 2026-08-24 | 14.54 | n/a | |
| PEG as of 2026-08-24 | 1.19 | n/a | |
| Net margin as of 2026-08-24 | +35.3% | -151.2% | EXEL higher |
| Gross margin as of 2026-08-24 | +96.5% | n/a | |
| Operating margin as of 2026-08-24 | +39.9% | -165.9% | EXEL higher |
| ROE as of 2026-08-24 | +42.5% | -41.5% | EXEL higher |
| ROA as of 2026-08-24 | +32.0% | -33.4% | EXEL higher |
| Debt / equity as of 2026-08-24 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-24 | +9.2% | +39.0% | TNGX higher |
| Revenue CAGR (3y) SEC XBRL | +9.5% | +35.9% | TNGX higher |
| Beta as of 2026-08-24 | 0.47 | 1.16 | |
| 1-year return as of 2026-08-21 close | +39.7% | +240.7% | TNGX higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.